Conditions

This post was originally published on this site The Phase 1 trial evaluating Curis‘ investigational immunotherapy CA-170 for advanced cancers has dosed its first mesothelioma patient, the company announced. The trial (NCT02812875), currently enrolling participants, will test the therapy in adults with advanced solid tumors, including mesothelioma, or lymphomas who failed to respond to standard therapies. CA-170 is…

This post was originally published on this site The U.S. Food and Drug Administration has approved the use of Keytruda (pembrolizumab) as a treatment for melanoma patients with stage 3 disease — cancer cells have spread to the lymph nodes but not to distant organs — who have undergone complete resection of a tumor. The approval…

This post was originally published on this site Testing for specific gene mutations may help predict the patients with glioblastoma who will respond to immunotherapy, according to new research. The findings also suggest a therapeutic target that could lead to improved immunotherapy in these patients. The study with those findings, “Immune and genomic correlates of…

This post was originally published on this site The U.S. Food and Drug Administration has accepted Merck‘s application seeking accelerated approval of Keytruda (pembrolizumab) for the treatment of advanced small cell lung cancer (SCLC) patients who failed at least two prior therapies. The supplemental biologics license application — based on results from the Phase 1b KEYNOTE-028 trial (NCT02054806) and the ongoing KEYNOTE-158…

This post was originally published on this site The U.S. Food and Drug Administration has placed a partial clinical hold on Xencor’s Phase 1 clinical trial of XmAb14045 for acute myeloid leukemia and other CD123-positive blood cancers because of two patient deaths that appear to be possibly related to the investigational therapy. A partial clinical hold…

This post was originally published on this site Pharmatest Services, in collaboration with Taconic Biosciences, has developed a new experimental mouse model with a human immune system specifically engineered to study bone metastasis — a frequent consequence of many cancers, including breast, prostate, and lung cancer. “Despite its high frequency in breast, prostate, and lung cancer…

This post was originally published on this site Elderly people with early-stage lung cancer might also benefit from stereotactic body radiation therapy (SBRT), finds a study of more than 1,000 patients. The study, “Stereotactic Body Radiation Therapy in Octo- and Nonagenarians for the Treatment of Early-Stage Lung Cancer,” appeared in the International Journal of Radiation Oncology • Biology…

This post was originally published on this site The European Commission (EC) granted marketing authorization to Roche for Tecentriq (atezolizumab) as a monotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior treatment with chemotherapy, the company announced in a press release. Tecentriq can be administered regardless of PD-L1 status, and patients that have EGFR-activating mutations or ALK-positive tumor…

This post was originally published on this site Health Canada has approved Yescarta (axicabtagene ciloleucel) as a treatment for adults with diffuse large B-cell lymphoma (DLBCL) who have already received two or more lines of systemic therapy. Specifically, the agency’s Notice of Compliance covers relapsed or refractory patients with unspecified DLBCL, primary mediastinal (thymic) large…

This post was originally published on this site The U.S. Food and Drug Administration has granted priority review to Roche‘s polatuzumab vedotin in combination with Rituxan (rituximab) and the chemotherapy bendamustine for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The FDA is expected to make a decision on whether to approve…

This post was originally published on this site A Phase 1 trial testing the combination of ADCT-402 (loncastuximab tesirine) with Imbruvica (ibrutinib) for advanced diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL) has dosed the first patient. Patient enrollment, for a planned total of 60 participants, is ongoing in the U.S. and Belgium. More information…

This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted priority review to Revlimid (lenalidomide) in combination with Rituxan (rituximab) for patients with previously treated follicular and marginal zone lymphoma. A decision on whether to approve the treatment combination is expected by June 27. Celgene’s supplemental New Drug Application…